Hck

Other Angiogenesis Related Inhibitors

Src FGFR HIF Bcr-Abl Syk VDA FLT3 FAK BTK ANGPTL

Cat.No.	Product Name	Information	Product Use Citations
E2834	Hck-IN-1	Hck-IN-1, a selective Nef-dependent Hck inhibitor, blocks the kinase activity of the Nef:Hck complex in vitro with an IC50 value of 2.8 μM, whereas its activity against Hck alone is >20 μM, also blocks wild-type HIV-1 replication with an IC50 value in the 100-300 nM range.
S1064	Masitinib	Masitinib is a novel inhibitor for Kit (c-Kit) and PDGFRα/β with IC50 of 200 nM and 540 nM/800 nM, weak inhibition to ABL and c-Fms. Phase 3.	Cancer Res, 2025, 10.1158/0008-5472.CAN-24-2220 iScience, 2024, 27(10):110862 bioRxiv, 2024, 2023.11.21.568071
S2622	PP121	PP-121 is a multi-targeted inhibitor of PDGFR, Hck, mTOR, VEGFR2, Src and Abl with IC50 of 2 nM, 8 nM, 10 nM, 12 nM, 14 nM and 18 nM, also inhibits DNA-PK with IC50 of 60 nM.	Life Sci Alliance, 2021, 4(2)e202000882 PLoS One, 2016, 11(10):e0164895 Biochem Biophys Res Commun, 2015, 465(1):137-44
E2643	TL02-59	TL02-59 is an orally active, selective Src-family kinase Fgr inhibitor with an IC50 of 0.03 nM.